1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU Health Experts On How ‘Optimization’ Could Improve Benefit Of New Cancer Drugs

 
• By Eliza Slawther

EU health policy experts including the European Medicines Agency’s Emer Cooke discuss ways to optimize the use of innovative cancer medicines, given that many new drugs fail to offer notable clinical benefits compared to existing therapies.

pills
Dose optimization is important in oncology, health experts say • Source: Alamy

Innovative new cancer drugs often provide no added clinical benefit when compared against existing therapies, something that could be explained – at least in part – by the fact that these medicines are not being used to treat patients in the best way possible.

This is according to several EU health policy experts, including Belgian deputy prime minister and minister of health and social...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By Sue Sutter

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 
• By Eliza Slawther

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.